Table 3 Univariate analysis: Influence on TTP (second-line)

Age > 65 years

6 vs. 7

0.00-12.79

3.36

n.s.

5.64-8.36

0.7

Age < 35 years

3 vs. 7

0.23-5.77

1.41

0.026

5.67-8.33

0.68

Stage 4 at diagnosis

6 vs. 7

5.52-8.48

0.76

n.s.

0.39-11.61

2.86

Grading (1,2 versus 3)

6 vs. 7

2.98-9.03

1.54

n.s.

5.6-8.41

0.72

Histologic type (ductal versus lobular)

6 vs. 9

4.86-7.14

0.58

n.s.

0.71-17.29

4.23

Positive hormone receptor status

6 vs. 7

4.64-7.36

0.7

n.s.

5.14-8.86

0.95

Time to recurrence < 12 months

6 vs. 7

3.41-8.59

1.32

n.s.

5.61-8.39

0.71

Visceral metastases

7 vs. 6

5.76-8.25

0.64

n.s.

0.00-12.53

3.33

Number of metastatic sites (1 versus 2)

14 vs. 6

9.56-18.44

2.26

0.013

5.02-6.98

0.5

Number of metastatic sites (2 versus > 2)

8 vs. 6

5.58-10.42

1.23

0.003

5.09-6.91

0.47

Trastuzumab from first-line palliative treatment

7 vs. 6

5.62-8.38

0.71

n.s.

4.65-7.35

0.69

Response to first-line trastuzumab-based therapy

7 vs. 6

5.25-8.75

0.89

n.s.

3.77-8.23

1.14

New metastatic sites at progression upon first-line trastuzumab-based therapy

7 vs. 6

4.81-9.19

1.12

n.s.

5.12-6.88

0.45